Used in the treatment of complement-mediated diseases, this antibody inhibits the cleavage of complement component C5, preventing the formation of the membrane attack complex (MAC). By blocking this pathway, it reduces inflammation and tissue damage associated with excessive complement activation. It is particularly applied in conditions like paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and other autoimmune or inflammatory disorders where uncontrolled complement activity plays a key role. Its high specificity for C5 makes it valuable in targeted therapies, minimizing off-target effects while preserving earlier components of the complement system involved in pathogen defense.